The Scientific Societies Clinical Guidelines recommends CA125 as a tumor marker for detecting recurrence, monitoring therapy, and determining the prognosis of women with ovarian cancer (Tang et al., 2008). Here, MUC16 is linked to ovarian carcinoma.